PreveCeutical Provides Clarification of News Release Announcing Update on Plan of Arrangement with BioGene Therapeutics Inc.November 20, 2025 12:26 PM EST | Source: PreveCeutical Medical Inc.Vancouver, British Columbia--(Newsfile Corp. - November 20, 2025) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) (the "Company" or "PreveCeutical"), announces that, further to its news release of earlier today, the Company wishes to clarify that shareholders of record of November 24, 20 ...

NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATESVancouver, British Columbia--(Newsfile Corp. - October 30, 2025) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) (the "Company" or "PreveCeutical"), is pleased to announce that, further to its news releases of August 5, 2025, September 5, 2025 and October 10, 2025 it has closed a second tranche (the "Second Tranche") of its previously announced $1,200,000 non-brokered private placement (the " ...

Core Points - PreveCeutical Medical Inc. has closed an initial tranche of a $1,000,000 non-brokered private placement, raising $646,500 through the issuance of 16,162,500 units at a price of $0.04 per unit [1][4] - Each unit consists of one common share and one-half of a share purchase warrant, with warrants exercisable at $0.06 for 24 months, subject to an acceleration right [2][3] - The proceeds from the initial tranche will be used for outstanding payables, operating expenses, and general working capital [4] Financial Details - The initial tranche raised gross proceeds of $646,500 from the issuance of 16,162,500 units at $0.04 each [1] - Finders fees paid included $23,600 in cash and 590,000 finder's warrants, also exercisable at $0.06 for 24 months [3] Future Plans - The company intends to close a second tranche for the remainder of the offering in the coming weeks [4] - All securities issued are subject to a hold period of four months and one day post-closing [4] Company Overview - PreveCeutical is focused on developing innovative preventive and curative therapies using organic and nature-identical products, with five active research and development programs [6]

Core Viewpoint - PreveCeutical Medical Inc. has entered into a definitive arrangement agreement to spin out 12,000,000 common shares of its subsidiary BioGene Therapeutics Inc. to its shareholders through a share capital reorganization [1][2]. Group 1: Arrangement Details - The existing common shares of PreveCeutical will be renamed as Class A common shares, and a new class of voting common shares will be created [2]. - Each PreveCeutical Class A Share will be exchanged for one New PreveCeutical Share, with the BioGene Spinout Shares distributed on a pro rata basis [2]. - Post-arrangement, shareholders will own shares in both BioGene and PreveCeutical, with BioGene focusing on Dual Gene Therapy and PreveCeutical on preventive and curative therapies [2]. Group 2: Approval Process - The arrangement requires approval from the Supreme Court of British Columbia and a two-thirds affirmative vote from PreveCeutical shareholders at the annual general and special meeting scheduled for October 10, 2025 [3][5]. - Following shareholder and court approval, the board will set an effective date for the arrangement [3]. Group 3: Trading and Compliance - New PreveCeutical Shares will continue trading on the Canadian Securities Exchange, OTCQB, and Frankfurt Stock Exchange, while BioGene Shares will not be listed on any exchange but will be a reporting issuer in British Columbia, Alberta, and Ontario [4]. - BioGene will comply with continuous disclosure obligations under applicable Canadian securities laws [4]. Group 4: Company Overview - PreveCeutical is a health sciences company focused on developing innovative preventive and curative therapies using organic and nature identical products [7]. - The company has five research and development programs, including dual gene therapy for diabetes and obesity, Nature Identical™ peptides, and non-addictive analgesic peptides [7].